Progress on Multi-disciplinary Combined Therapy for Locally Advanced Hypopharyngeal Carcinoma
-
摘要:
由于下咽独特的位置与功能，器官功能的保全与生存的提高同样重要，对于下咽癌的最佳保喉策略在持续探索中。手术、放疗、化疗、分子靶向治疗以及免疫治疗等手段的不断进步，新的保喉治疗策略不断涌现。本文主要介绍下咽癌保喉治疗策略的确立、发展以及对未来的展望。
Abstract:Given the important position and function of the hypopharynx, the preservation of organ function and survival improvement are equally important. The optimal role of multi-disciplinary combined treatment modality becoming increasingly important. The optimal laryngeal preservation strategy for hypopharyngeal cancer is under continuous exploration. With the constant research of surgery, radiotherapy, chemotherapy, and molecular targeted therapy, new laryngeal preservation strategies continue to emerge. Herein, we primarily summarize the advances in multi-disciplinary combined treatment and the future direction in the treatment of hypopharyngeal carcinoma.
-
Competing interests: The authors declare that they have no competing interests.利益冲突声明：所有作者均声明不存在利益冲突。作者贡献：罗 希：文章撰写易俊林：文章修改
-
表 1 下咽癌的保喉策略探索的相关研究
Table 1 Key trials of laryngeal preservation strategies for hypopharyngeal carcinoma
下载: 导出CSV
-
[1] Carvalho AL, Nishimoto IN, Califano JA, et al. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database[J]. Int J Cancer, 2005, 114(5): 806-816. doi: 10.1002/ijc.20740
[2] Hall SF, Groome PA, Irish J, et al. The natural history of patients with squamous cell carcinoma of the hypopharynx[J]. Laryngoscope, 2008, 118(8): 1362-1371. doi: 10.1097/MLG.0b013e318173dc4a
[3] De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study[J]. Lancet Oncol, 2014, 15(1): 23-34. doi: 10.1016/S1470-2045(13)70546-1
[4] Decker DA, Drelichman A, Jacobs J, et al. Adjuvant chemotherapy with cis-diamminodichloroplatinum Ⅱ and 120-hour infusion 5-fluorouracil in Stage Ⅲ and Ⅳ squamous cell carcinoma of the head and neck[J]. Cancer, 1983, 51(8): 1353-1355. doi: 10.1002/1097-0142(19830415)51:8<1353::AID-CNCR2820510805>3.0.CO;2-I
[5] Ensley JF, Jacobs JR, Weaver A, et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck[J]. Cancer, 1984, 54(5): 811-814. doi: 10.1002/1097-0142(19840901)54:5<811::AID-CNCR2820540508>3.0.CO;2-E
[6] Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer[J]. N Engl J Med, 1991, 324(24): 1685-1690. doi: 10.1056/NEJM199106133242402
[7] Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase Ⅲ trial. EORTC Head and Neck Cancer Cooperative Group[J]. J Natl Cancer Inst, 1996, 88(13): 890-899. doi: 10.1093/jnci/88.13.890
[8] Lefebvre JL, Andry G, Chevalier D, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891[J]. Ann Oncol, 2012, 23(10): 2708-2714. doi: 10.1093/annonc/mds065
[9] Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer[J]. Lancet, 2000, 355(9208): 949-955. doi: 10.1016/S0140-6736(00)90011-4
[10] Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site[J]. Radiother Oncol, 2011, 100(1): 33-40. doi: 10.1016/j.radonc.2011.05.036
[11] Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer[J]. N Engl J Med, 2003, 349(22): 2091-2098. doi: 10.1056/NEJMoa031317
[12] Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer[J]. J Clin Oncol, 2013, 31(7): 845-852. doi: 10.1200/JCO.2012.43.6097
[13] Henriques De Figueiredo B, Fortpied C, Menis J, et al. Long-term update of the 24954 EORTC phase Ⅲ trial on larynx preservation[J]. Eur J Cancer, 2016, 65: 109-112. doi: 10.1016/j.ejca.2016.06.024
[14] Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs. alternating chemotherapy and radiotherapy[J]. J Natl Cancer Inst, 2009, 101(3): 142-152. doi: 10.1093/jnci/djn460
[15] Prades JM, Lallemant B, Garrel R, et al. Randomized phase Ⅲ trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma[J]. Acta Otolaryngol, 2010, 130(1): 150-155. doi: 10.3109/00016480902914080
[16] Yoon MS, Chung WK, Ahn SJ, et al. Concurrent chemoradiotherapy with cisplatin and fluorouracil for locally advanced hypopharyngeal carcinoma[J]. Acta Otolaryngol, 2008, 128(5): 590-596. doi: 10.1080/00016480701596021
[17] 易俊林, 高黎, 徐震纲, 等. 术前同期放化与单纯放疗局部晚期头颈部鳞癌的Ⅲ期临床研究[J]. 中华放射肿瘤学杂志, 2011, 20(5): 363-367. doi: 10.3760/cma.j.issn.1004-4221.2011.05.001 Yi JL, Gao L, Xu ZG, et al. Phse Ⅲ study of preoperative concurrent chemoradiotherapy compared with preoperative radiotherapy alone in the treatment of locally advanced head and neck squamons cell carcinona[J]. Zhonghua Fang She Zhong Liu Xue Za Zhi, 2011, 20(5): 363-367. doi: 10.3760/cma.j.issn.1004-4221.2011.05.001
[18] 黄辉, 徐震纲, 唐平章, 等. 梨状窝癌术前同步放化疗对手术并发症影响的临床研究[J]. 中华耳鼻咽喉头颈外科杂志, 2011, 46(2): 114-117. Hui H, Xu ZG, Tang PZ, et al. Clinical analysis of surgical complications after preoperative concurrent chemoradiotherapy of pyriform sinus cancer[J]. Zhonghua Er Bi Yan Hou Tou Jing Eai Ke Za Zhi, 2011, 46(2): 114-117.
[19] 张宗敏, 唐平章, 徐震纲, 等. 不同术前放射治疗剂量在下咽鳞癌综合治疗中的意义[J]. 中华放射肿瘤学杂志, 2004, 13(1): 1-3. doi: 10.3760/j.issn:1004-4221.2004.01.001 Zhang ZM, Tang PZ, Xu ZG, et al. Significance of different preoperative radiotherapy doses in combined therapy for hypopharyngeal squamous cell carcinoma[J]. Zhonghua Fang She Zhong Liu Xue Za Zhi, 2004, 13(1): 1-3. doi: 10.3760/j.issn:1004-4221.2004.01.001
[20] 张宗敏, 唐平章, 徐震纲, 等. 下咽鳞癌不同治疗方案的临床分析[J]. 中华肿瘤杂志, 2005, 27(1): 48-51. doi: 10.3760/j.issn:0253-3766.2005.01.013 Zhang ZM, Tang PZ, Xu ZG, et al. Long-term results of different treatment modalities in 464 hypopharyngeal squamous-cell carcinoma patients[J]. Zhonghua Zhong Liu Za Zhi, 2005, 27(1): 48-51. doi: 10.3760/j.issn:0253-3766.2005.01.013
[21] Luo X, Huang X, Liu S, et al. Response-Adapted Treatment Following Radiotherapy in Patients With Resectable Locally Advanced Hypopharyngeal Carcinoma[J]. JAMA Netw Open, 2022, 5(2): e220165. doi: 10.1001/jamanetworkopen.2022.0165
[22] Yi J, Huang X, Xu Z, et al. Phase Ⅲ randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma[J]. Oncotarget, 2017, 8(27): 44842-44850. doi: 10.18632/oncotarget.15107
[23] Dietz A, Wichmann G, Kuhnt T, et al. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-Ⅱ[J]. Ann Oncol, 2018, 29(10): 2105-2114. doi: 10.1093/annonc/mdy332
[24] Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase Ⅱ study[J]. J Clin Oncol, 2013, 31(7): 853-859. doi: 10.1200/JCO.2012.42.3988
[25] Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation[J]. J Natl Cancer Inst, 2009, 101(7): 498-506. doi: 10.1093/jnci/djp007
[26] 杨一帆, 王茹, 房居高, 等. 中晚期下咽癌诱导化疗筛选综合治疗的单臂前瞻性研究: 单中心260例报告[J]. 中华耳鼻咽喉头颈外科杂志, 2020, 55(12): 1143-1153. doi: 10.3760/cma.j.cn115330-20200417-00306 Yang YF, Wang R, Fang JG, et al. A single-arm prospective study on induction chemotherapy and subsequent comprehensive therapy for advanced hypopharyngeal squamous cell carcinoma: report of 260 cases in a single center[J]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2020, 55(12): 1143-1153. doi: 10.3760/cma.j.cn115330-20200417-00306
[27] Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer[J]. N Engl J Med, 2007, 357(17): 1705-1715. doi: 10.1056/NEJMoa070956
[28] Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer[J]. N Engl J Med, 2007, 357(17): 1695-1704. doi: 10.1056/NEJMoa071028
[29] Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(3): 257-264. doi: 10.1016/S1470-2045(13)70011-1
[30] Cohen EE, Karrison TG, Kocherginsky M, et al. Phase Ⅲ randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer[J]. J Clin Oncol, 2014, 32(25): 2735-2743. doi: 10.1200/JCO.2013.54.6309
[31] Hitt R, Grau JJ, López-Pousa A, et al. A randomized phase Ⅲ trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer[J]. Ann Oncol, 2014, 25(1): 216-225. doi: 10.1093/annonc/mdt461
[32] Ghi MG, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase Ⅱ-Ⅲ trial[J]. Ann Oncol, 2017, 28(9): 2206-2212. doi: 10.1093/annonc/mdx299
[33] Luo X, Huang X, Luo J, et al. Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial[J]. BMC Cancer, 2022, 22(1): 1235. doi: 10.1186/s12885-022-10306-y
[34] Martin A, Jäckel MC, Christiansen H, et al. Organ preserving transoral laser microsurgery for cancer of the hypopharynx[J]. Laryngoscope, 2008, 118(3): 398-402. doi: 10.1097/MLG.0b013e31815aeda3
[35] Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016, 17(7): 956-965. doi: 10.1016/S1470-2045(16)30066-3
[36] Durmus K, Kucur C, Uysal IO, et al. Feasibility and clinical outcomes of transoral robotic surgery and transoral robot-assisted carbon dioxide laser for hypopharyngeal carcinoma[J]. J Craniofac Surg, 2015, 26(1): 235-237. doi: 10.1097/SCS.0000000000001185
[37] Park YM, Kim WS, Byeon HK, et al. Feasiblity of transoral robotic hypopharyngectomy for early-stage hypopharyngeal carcinoma[J]. Oral Oncol, 2010, 46(8): 597-602. doi: 10.1016/j.oraloncology.2010.05.003
[38] Dziegielewski PT, Kang SY, Ozer E. Transoral robotic surgery (TORS) for laryngeal and hypopharyngeal cancers[J]. J Surg Oncol, 2015, 112(7): 702-706. doi: 10.1002/jso.24002
[39] Seiert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016, 17(7): 956-965. doi: 10.1016/S1470-2045(16)30066-3
[40] Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck[J]. N Engl J Med, 2016, 375(19): 1856-1867. doi: 10.1056/NEJMoa1602252
[41] Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 393(10167): 156-167. doi: 10.1016/S0140-6736(18)31999-8
[42] Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10212): 1915-1928. doi: 10.1016/S0140-6736(19)32591-7
[43] Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial[J]. Lancet Oncol, 2021, 22(4): 450-462. doi: 10.1016/S1470-2045(20)30737-3
[44] Machiels JP, Tao Y, Burtness B, et al. Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412[J]. Future Oncol, 2020, 16(18): 1235-1243. doi: 10.2217/fon-2020-0184
[45] Bourhis J, Tao Y, Sun X, et al. LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-HNSCC): Randomized phase Ⅲ GORTEC-REACH trial[J]. Ann Oncol, 2021, 32(suppl_5): S1310.
-
期刊类型引用(2)
1. 王海宏，宋玉，贺凡，杨兵，唐东昕，吴文宇. 基于伏邪理论探讨循环肿瘤细胞与结直肠癌复发转移的相关性. 中医杂志. 2024(19): 1983-1987 . 
百度学术
2. 阙祖俊，田建辉. 根除休眠播散肿瘤细胞防止肿瘤转移的潜在治疗药物的研究进展. 中国肿瘤生物治疗杂志. 2024(11): 1146-1151 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 2569
- HTML全文浏览量: 769
- PDF下载量: 1004
- 被引次数: 2
